Filing summary
Gain Therapeutics, Inc. (NASDAQ: GANX) filed this Form 8-K concerning executive changes. The report covers events beginning September 22, 2026, and was signed September 28, 2026.
Key changes
- Gianluca Fuggetta, Senior Vice President of Finance, principal financial officer and principal accounting officer, notified the company on September 22 that he would resign effective September 30, 2026, to pursue other opportunities.
- On September 24, the board appointed Gene Mack, the company’s current President and CEO, as interim CFO, principal financial officer and principal accounting officer, effective October 1, 2026. He will retain his President and CEO roles while serving in the interim positions.
- The company is searching for a permanent replacement. Mack’s compensation and other material employment terms will remain unchanged.
Financial information and outlook
This filing reports no revenue, earnings, cash flow, margin, debt, liquidity, guidance or other operating metrics. It provides no financial outlook or quantified contingencies.
Investor points to verify
- Whether the company appoints a permanent principal financial officer and principal accounting officer, and when.
- Whether the interim combination of CEO and senior finance and accounting responsibilities results in any subsequent governance or control changes.